Search - tctmd.com

Displaying 161 - 180 of 722

Sort: Relevancy | Date

Presentation TCT 2022

Late-Breaking Evidence from RADIANCE II

Presenter: Michel Azizi

September 19, 2022

Presentation TCT 2022

Introduction and Objectives

Presenter: Felix Mahfoud

September 19, 2022

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Presentation TCT 2022

NEXT STEPS: How Will Renal Denervation be Implemented in Practice?

Presenter: Naomi Fisher

September 18, 2022

Presentation TCT 2022

Clinical Implications of RADIANCE II and Recent Renal Denervation Trials: A Clinician’s Perspective

Presenter: Patrick O'Gara

September 18, 2022

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Todd Neale

September 18, 2022

Presentation TCT 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presenter: Deepak Bhatt

September 18, 2022

Presentation TCT 2022

Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Presenter: Ajay Kirtane

September 18, 2022

Presentation TCT 2022

Update on the RADIANCE Clinical Trials Program (Ultra-Sound Renal Denervation)

Presenter: Naomi Fisher

September 17, 2022

Presentation TCT 2022

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

Presenter: David Kandzari

September 17, 2022

Presentation TCT 2022

TCT 215: Association between Renal Sympathetic Denervation and Arterial Stiffness: the ASORAS Study.

Presenter: Victor Zeijen

September 17, 2022

Presentation TCT 2022

TCT 214: Single Ablation Renal Denervation – The RADAR Study Experience with the Metavention iRF System

Presenter: Horst Sievert

September 17, 2022

Presentation TCT 2022

TCT 212: Twenty-Four Month Results in Patients with Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial

Presenter: Roland Schmieder

September 17, 2022

Presentation

TCT 211: Home Blood Pressure Response to Ultrasound Renal Denervation - a Patient-level Pooled Analysis of the RADIANCE-HTN SOLO and TRIO Randomised, Sham-controlled Trials

Presenter: Andrew Sharp

September 17, 2022

Presentation TCT 2022

TCT 213: Impact of Cardiac Neuromodulation Therapy (CNT) on Systolic Blood Pressure and Pulse Pressure in Hypertensive Patients Indicated for a Pacemaker: Results of a Crossover Study

Presenter: Daniel Burkhoff

September 17, 2022

Presentation TCT 2022

TCT 210: Long-term blood pressure results after renal sympathetic denervation using endovascular ultrasound

Presenter: Karl Fengler

September 17, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2022

Todd Neale

August 01, 2022

News Daily News

RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation

Todd Neale

July 26, 2022

Presentation EuroPCR 2022

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Presenter: Felix Mahfoud

May 20, 2022

Advertisement

Late-Breaking Evidence from RADIANCE II

Introduction and Objectives

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

NEXT STEPS: How Will Renal Denervation be Implemented in Practice?

Clinical Implications of RADIANCE II and Recent Renal Denervation Trials: A Clinician’s Perspective

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Update on the RADIANCE Clinical Trials Program (Ultra-Sound Renal Denervation)

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

TCT 215: Association between Renal Sympathetic Denervation and Arterial Stiffness: the ASORAS Study.

TCT 214: Single Ablation Renal Denervation – The RADAR Study Experience with the Metavention iRF System

TCT 212: Twenty-Four Month Results in Patients with Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial

TCT 211: Home Blood Pressure Response to Ultrasound Renal Denervation - a Patient-level Pooled Analysis of the RADIANCE-HTN SOLO and TRIO Randomised, Sham-controlled Trials

TCT 213: Impact of Cardiac Neuromodulation Therapy (CNT) on Systolic Blood Pressure and Pulse Pressure in Hypertensive Patients Indicated for a Pacemaker: Results of a Crossover Study

TCT 210: Long-term blood pressure results after renal sympathetic denervation using endovascular ultrasound

New Faces, New Formats, New Tech: What to Expect From TCT 2022

TCTMD’s Top 10 Most Popular Stories for July 2022

RADIANCE II Top-Line Results Promising for Ultrasound Renal Denervation

Blood pressure and MACE reductions after renal denervation: 3-year GSR results

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content